{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:22:06Z","timestamp":1790731326895,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,15]],"date-time":"2020-02-15T00:00:00Z","timestamp":1581724800000},"content-version":"am","delay-in-days":351,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.revmed.2018.11.005","type":"journal-article","created":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T00:49:48Z","timestamp":1544057388000},"page":"178-183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Actualit\u00e9s dans le m\u00e9lanome cutan\u00e9"],"prefix":"10.1016","volume":"40","author":[{"given":"C.","family":"Longvert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Saiag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2018.11.005_bib0280","unstructured":"Les cancers en France [Internet]. Disponible sur\u00a0: http:\/\/www.e-cancer.fr\/ressources\/cancers_en_france\/#page=1 [cit\u00e9 1\u00a0mai 2018]."},{"key":"10.1016\/j.revmed.2018.11.005_bib0285","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009\u00a0AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2018.11.005_bib0290","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejca.2004.10.016","article-title":"Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure","volume":"41","author":"Gandini","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.revmed.2018.11.005_bib0295","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.annepidem.2008.04.006","article-title":"Sunburns and risk of cutaneous melanoma: does age matter? A comprehensive meta-analysis","volume":"18","author":"Dennis","year":"2008","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.revmed.2018.11.005_bib0300","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1158\/1055-9965.EPI-09-1249","article-title":"Indoor tanning and risk of melanoma: a case-control study in a highly exposed population","volume":"19","author":"Lazovich","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.revmed.2018.11.005_bib0305","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.ejca.2005.03.034","article-title":"Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors","volume":"41","author":"Gandini","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.revmed.2018.11.005_bib0310","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejca.2004.10.015","article-title":"Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi","volume":"41","author":"Gandini","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.revmed.2018.11.005_bib0315","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1001\/archderm.139.12.1620","article-title":"Cutaneous melanomas associated with nevi","volume":"139","author":"Bevona","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.revmed.2018.11.005_bib0320","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1001\/archderm.137.10.1343","article-title":"Is dermoscopy (epiluminescence microscopy) useful for the diagnosis of melanoma? Results of a meta-analysis using techniques adapted to the evaluation of diagnostic tests","volume":"137","author":"Bafounta","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.revmed.2018.11.005_bib0325","first-page":"669","article-title":"Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting","volume":"159","author":"Vestergaard","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.revmed.2018.11.005_bib0330","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.revmed.2018.11.005_bib0335","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","author":"Cancer Genome Atlas Network","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.revmed.2018.11.005_bib0340","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.revmed.2018.11.005_bib0345","first-page":"1071","article-title":"Cutaneous melanoma: from pathogenesis to therapy (Review)","volume":"52","author":"Leonardi","year":"2018","journal-title":"Int J Oncol"},{"key":"10.1016\/j.revmed.2018.11.005_bib0350","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.revmed.2018.11.005_bib0355","doi-asserted-by":"crossref","first-page":"e35309","DOI":"10.1371\/journal.pone.0035309","article-title":"Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials","volume":"7","author":"Lovly","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.revmed.2018.11.005_bib0360","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"Curtin","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2018.11.005_bib0365","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/2159-8290.CD-12-0313","article-title":"Elucidating distinct roles for NF1\u00a0in melanomagenesis","volume":"3","author":"Maertens","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.revmed.2018.11.005_bib0370","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1755-148X.2010.00671.x","article-title":"Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure","volume":"23","author":"Handolias","year":"2010","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.revmed.2018.11.005_bib0375","doi-asserted-by":"crossref","first-page":"6821","DOI":"10.1158\/1078-0432.CCR-08-0575","article-title":"KIT gene mutations and copy number in melanoma subtypes","volume":"14","author":"Beadling","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.revmed.2018.11.005_bib0380","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-12-0052","article-title":"Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma","volume":"18","author":"Menzies","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.revmed.2018.11.005_bib0385","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.revmed.2018.11.005_bib0390","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/jdv.14064","article-title":"French updated recommendations in Stages I to III melanoma treatment and management","volume":"31","author":"Guillot","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.revmed.2018.11.005_bib0395","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa1310460","article-title":"Final trial report of sentinel-node biopsy versus nodal observation in melanoma","volume":"370","author":"Morton","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2018.11.005_bib0400","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(16)00141-8","article-title":"Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3\u00a0trial","volume":"17","author":"Leiter","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.revmed.2018.11.005_bib0405","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion dissection or observation for sentinel-node metastasis in melanoma","volume":"376","author":"Faries","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2018.11.005_bib0410","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","article-title":"Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma","volume":"18","author":"Middleton","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2018.11.005_bib0415","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.2007.12.7837","article-title":"Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials","volume":"26","author":"Korn","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2018.11.005_bib0420","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2018.11.005_bib0425","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2018.11.005_bib0430","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2018.11.005_bib0435","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2018.11.005_bib0440","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2018.11.005_bib0445","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2018.11.005_bib0450","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2018.11.005_bib0455","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2018.11.005_bib0460","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2\u00a0study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.revmed.2018.11.005_bib0465","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2018.11.005_bib0470","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2018.11.005_bib0475","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3\u00a0randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2018.11.005_bib0480","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature08902","article-title":"RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF","volume":"464","author":"Poulikakos","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.revmed.2018.11.005_bib0485","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2018.11.005_bib0490","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2018.11.005_bib0495","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600\u00a0BRAF-mutant melanoma: a multicentre, double-blind, phase 3\u00a0randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2018.11.005_bib0500","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2018.11.005_bib0505","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13045-016-0369-8","article-title":"Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients","volume":"10","author":"Daud","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.revmed.2018.11.005_bib0510","unstructured":"Patients atteints de m\u00e9lanome de stade III inop\u00e9rable ou de stade IV\u00a0-\u00a0Synth\u00e8se\u00a0-\u00a0Ref\u00a0: RECOMELASYNTH17 | Institut National Du Cancer [Internet]. Disponible sur\u00a0: http:\/\/www.e-cancer.fr\/Expertises-et-publications\/Catalogue-des-publications\/Patients-atteints-de-melanome-de-stade-III-inoperable-ou-de-stade-IV-Synthese [cit\u00e9 6\u00a0mai 2018]."},{"key":"10.1016\/j.revmed.2018.11.005_bib0515","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3\u00a0trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.revmed.2018.11.005_bib0520","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1200\/JCO.2017.75.6270","article-title":"Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma","volume":"36","author":"Robert","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2018.11.005_bib0525","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/annonc\/mdx686","article-title":"Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy","volume":"29","author":"Rotte","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.revmed.2018.11.005_bib0530","doi-asserted-by":"crossref","first-page":"e1442166","DOI":"10.1080\/2162402X.2018.1442166","article-title":"Efficacy of combined hypo-fractionated radiotherapy and anti-PD-1\u00a0monotherapy in difficult-to-treat advanced melanoma patients","volume":"7","author":"Roger","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.revmed.2018.11.005_bib0535","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3\u00a0trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.revmed.2018.11.005_bib0540","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2018.11.005_bib0545","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2018.11.005_bib0275","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866318311780?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866318311780?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:40:23Z","timestamp":1759336823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866318311780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0248866318311780"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2018.11.005","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Actualit\u00e9s dans le m\u00e9lanome cutan\u00e9","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2018.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}